Skip to main content
×
×
Home

Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review

  • Sherif Hanafy Mahmoud (a1) and Jenna Buxton (a1)
Abstract

Seizures are important complications following a subarachnoid hemorrhage (SAH). The evidence for the use of antiepileptic drugs (AEDs) in treatment and prevention of those seizures is conflicting. The purpose of this review is to provide an up-to-date evidence summary of the incidence and outcomes of seizures following an SAH as well as the use of different AEDs post-SAH in order to evaluate the need for seizure prophylaxis, the choice of AEDs, and their dosing considerations in SAH patients. A literature search of PubMed, Medline, Embase, and the Cochrane Library was performed. A total of 37 studies were reviewed, mostly observational. Definitions of seizures in temporal relation to initial hemorrhage were variable. Similarly, the rates of seizures varied in the literature, ranging from 0 to 31%. Given the reported adverse outcomes associated with AED usage, seizure prophylaxis is not warranted. Levetiracetam appears to be better tolerated than phenytoin in SAH patients, though further research is needed. Higher initial dosing of levetiracetam might be required due to its enhanced clearance in SAH patients. In conclusion, there is a lack of quality evidence to definitively recommend the use of one AED over another. Further prospective research comparing the use of different AEDs in patients with an SAH is needed.

Crises convulsives et choix de médicaments antiépileptiques suite à une hémorragie sous-arachnoïdienne : une revue. Les crises convulsives constituent des complications importantes après une hémorragie sous-arachnoïdienne (HSA). Les données en faveur de l’utilisation de médicaments antiépileptiques (MAE) dans le traitement et la prévention de ces crises sont contradictoires. Le but de cette revue est de présenter une mise-à-jour sommaire des données sur l’incidence et l’issue des crises suite à une HSA ainsi que sur l’utilisation de différents MAE post HSA afin d’évaluer la nécessité d’une prophylaxie et le choix et le dosage des MAE chez les patients atteints d’une HSA. Nous avons effectué une recherche de la littérature indexée dans PubMed, Medline, Embase et la Bibliothèque Cochrane. Nous avons revu 37 études, surtout des études d’observation. Les définitions des crises en relation temporelle avec l’hémorragie initiale étaient variables. De même, les taux de crises convulsives variaient dans la littérature, allant de 0 à 31%. Étant donné les résultats défavorables rapportés avec l’utilisation de MAE, la prophylaxie des crises convulsives n’est pas justifiée. Bien que des recherches supplémentaires soient nécessaires, le lévétiracétam semble être mieux toléré que la phénytoïne chez les patients atteints d’une HSA. Une dose supérieure initiale de lévétiracétam peut être requise à cause de sa clairance augmentée chez ces patients. Il existe un manque de données de qualité en faveur d’une recommandation de l’utilisation d’un MAE plutôt que d’un autre. De nouvelles études prospectives comparant l’utilisation de différents MAE chez les patients atteints d’une HSA devront être réalisées.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review
      Available formats
      ×
Copyright
Corresponding author
Correspondence to: Sherif Hanafy Mahmoud, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 3-228 Edmonton Clinic Health Academy, Edmonton, Alberta, Canada, T6G 1C9. Email: smahmoud@ualberta.ca
References
Hide All
1. Connolly, ES Jr, Rabinstein, AA, Carhuapoma, JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737.
2. de Rooij, NK, Linn, FH, van der Plas, JA, Algra, A, Rinkel, GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78(12):1365-1372.
3. Diringer, MN, Bleck, TP, Claude Hemphill, J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211-240.
4. Marigold, R, Günther, A, Tiwari, D, Kwan, J. Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. Cochrane Database Syst Rev. 2013:(6):CD008710.
5. Lanzino, G, D’Urso, PI, Suarez, J, et al. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15(2):247-256.
6. Guyatt, G, Oxman, AD, Akl, EA, et al. GRADE guidelines, 1: introduction. GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
7. Choi, KS, Chun, HJ, Yi, HJ, Ko, Y, Kim, YS, Kim, JM. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. J Korean Neurosurg Soc. 2009;46(2):93-98.
8. Byrne, JV, Boardman, P, Ioannidis, I, Adcock, J, Traill, Z. Seizures after aneurysmal subarachnoid hemorrhage treated with coil embolization. Neurosurgery. 2003;52(3):545-552; discussion 550–2.
9. Fung, C, Balmer, M, Murek, M, et al. Impact of early-onset seizures on grading and outcome in patients with subarachnoid hemorrhage. J Neurosurg. 2015;122(2):408-413.
10. Hart, RG, Byer, JA, Slaughter, JR, Hewett, JE, Easton, JD. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery. 1981;8(4):417-421.
11. Lin, YJ, Chang, WN, Chang, HW, et al. Risk factors and outcome of seizures after spontaneous aneurysmal subarachnoid hemorrhage. Eur J Neurol. 2008;15(5):451-457.
12. Pinto, AN, Canhao, P, Ferro, JM. Seizures at the onset of subarachnoid haemorrhage. J Neurol. 1996;243(2):161-164.
13. Butzkueven, H, Evans, AH, Pitman, A, et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology. 2000;55(9):1315-1320.
14. Lin, CL, Dumont, AS, Lieu, AS, et al. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(6):978-985.
15. Murphy-Human, T, Welch, E, Zipfel, G, Diringer, MN, Dhar, R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. World Neurosurg. 2011;75(2):269-274.
16. Huttunen, J, Kurki, MI, von Und, ZF, et al. Epilepsy after aneurysmal subarachnoid hemorrhage: a population-based, long-term follow-up study. Neurology. 2015;84(22):2229-2237.
17. Sundaram, MB, Chow, F. Seizures associated with spontaneous subarachnoid hemorrhage. Can J Neurol Sci. 1986;13(3):229-231.
18. Baker, CJ, Prestigiacomo, CJ, Solomon, RA. Short-term perioperative anticonvulsant prophylaxis for the surgical treatment of low-risk patients with intracranial aneurysms. Neurosurgery. 1995;37(5):863-870.
19. Rhoney, DH, Tipps, LB, Murry, KR, Basham, MC, Michael, DB, Coplin, WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2000;55(2):258-265.
20. Karamchandani, RR, Fletcher, JJ, Pandey, AS, Rajajee, V. Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2014;21(9):1507-1513.
21. Raper, DM, Kokabi, N, McGee-Collett, M. The efficacy of antiepileptic drug prophylaxis in the prevention of early and late seizures following repair of intracranial aneurysms. J Clin Neurosci. 2011;18(9):1174-1179.
22. Naidech, AM, Kreiter, KT, Janjua, N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583-587.
23. Dhakal, LP, Hodge, DO, Nagel, J, et al. Erratum to: safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (SAH) headache and meningismus. Neurocrit Care. 2015;22(3):422.
24. De Marchis, GM, Pugin, D, Meyers, E, et al. Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology. 2016;86(3):253-260.
25. Chumnanvej, S, Dunn, IF, Kim, DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60(1):99-102.
26. Ibrahim, GM, Fallah, A, Macdonald, RL. Clinical, laboratory, and radiographic predictors of the occurrence of seizures following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2013;119(2):347-352.
27. Mink, S, Muroi, C, Seule, M, Bjeljac, M, Keller, E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2011;113(8):644-648.
28. Taylor, S, Heinrichs, RJ, Janzen, JM, Ehtisham, A. Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage. Neurocrit Care. 2011;15(1):80-84.
29. Dennis, LJ, Claassen, J, Hirsch, LJ, Emerson, RG, Connolly, ES, Mayer, SA. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1136-1143.
30. Haines, SJ. Decerebrate posturing misinterpreted as seizure activity. Am J Emerg Med. 1988;6(2):173-177.
31. Jaja, BN, Attalla, D, Macdonald, RL, et al. The Subarachnoid Hemorrhage International Trialists (SAHIT) Repository: advancing clinical research in subarachnoid hemorrhage. Neurocrit Care. 2014;21(3):551-559.
32. Shah, D, Husain, AM. Utility of levetiracetam in patients with subarachnoid hemorrhage. Seizure. 2009;18(10):676-679.
33. Aim to prevent rebleeding and minimise neurological deficit in aneurysmal subarachnoid haemorrhage. Drugs Ther Perspect. 1996;8(10):8–11.
34. Dhakal, LP, Hodge, DO, Nagel, J, et al. Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (SAH) headache and meningismus. Neurocrit Care. 2015;22(3):414-421.
35. Little, AS, Kerrigan, JF, McDougall, CG, et al. Nonconvulsive status epilepticus in patients suffering spontaneous subarachnoid hemorrhage. J Neurosurg. 2007;106(5):805-811.
36. Hasan, D, Schonck, RS, Avezaat, CJ, Tanghe, HL, van Gijn, J, van der Lugt, PJ. Epileptic seizures after subarachnoid hemorrhage. Ann Neurol. 1993;33(3):286-291.
37. Yoon, SJ, Joo, JY, Kim, YB, Hong, CK, Chung, J. Effects of prophylactic antiepileptic drugs on clinical outcomes in patients with a good clinical grade suffering from aneurysmal subarachnoid hemorrhage. J Cerebrovasc Endovasc Neurosurg. 2015;17(3):166-172.
38. Claassen, J, Peery, S, Kreiter, KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology. 2003;60(2):208-214.
39. Rosengart, A, Huo, JD, Tolentino, J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg. 2007;107(2):253-260.
40. Panczykowski, D, Pease, M, Zhao, Y, et al. prophylactic antiepileptics and seizure incidence following subarachnoid hemorrhage: a propensity score-matched analysis. Stroke. 2016;47(7):1754-1760.
41. Patsalos, PN, Berry, DJ, Bourgeois, BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276.
42. Szaflarski, JP, Sangha, KS, Lindsell, CJ, Shutter, LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165-172.
43. Tartara, A, Galimberti, CA, Manni, R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991;32(3):335-340.
44. Fleishaker, JC, Pearson, LK, Peters, GR. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans: a putative measure of CYP3A induction. J Pharm Sci. 1995;84(3):292-294.
45. Spencer, DD, Jacobi, J, Juenke, JM, Fleck, JD, Kays, MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy. 2011;31(10):934-941.
46. Murphy-Human, T, Diringer, M, Zipfel, G, et al. Duration of seizure prophylaxis after subarachnoid hemorrhage (DOPAST): results of a randomized comparative effectiveness trial [abstract]. Presented at the 14th Annual Meeting of the Neurocritical Care Society. National Harbor, MD; 2016.
47. Rejdak, K, Papuc, E, Dropko, P, Stelmasiak, Z. Acute stroke-elicited epilepsia partialis continua responsive to intravenous sodium valproate. Neurol Neurochir Pol. 2008;42(2):157-160.
48. Kim, DW, Kim, TE, Ji, M, Chun, YI. Safety, tolerability, and pharmacokinetics of fosphenytoin loading in patients with subarachnoid hemorrhage. Clin Neuropharmacol. 2015;38(6):248-251.
49. Drust, A, Luchtmann, M, Firsching, R, Troger, U, Martens-Lobenhoffer, J, Bode-Boger, SM. Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function? Epilepsy Behav. 2012;23(4):394-395.
50. May, CC, Arora, S, Parli, SE, Fraser, JF, Bastin, MT, Cook, AM. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care. 2015;23(3):374-379.
51. Perucca, P, Gilliam, FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792-802.
52. Dewan, MC, Mocco, J. Current practice regarding seizure prophylaxis in aneurysmal subarachnoid hemorrhage across academic centers. J Neurointerv Surg. 2015;7(2):146-149.
53. Rush, B, Wiskar, K, Fruhstorfer, C, Hertz, P. Association between seizures and mortality in patients with aneurysmal subarachnoid hemorrhage: a nationwide retrospective cohort analysis. Seizure. 2016;41:66-69.
54. Szaflarski, JP, Meckler, JM, Szaflarski, M, Shutter, LA, Privitera, MD, Yates, SL. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7(2):140-147.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed